drugset / Trial / NCT06475599
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To demonstrate that anlotinib hydrochloride capsules combined with TQB2450 injection can significantly prolong progression-free survival (PFS) compared with chemotherapy in patients with recurrent or metastatic endometrial cancer that is non- microsatellite instability high (non-MSI-H) or DNA mismatch repair deficient (non-dMMR).
Timeline
- Start
- 2024-07
- Primary completion
- 2027-12
- Completion
- 2029-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benmelstobart | Monoclonal antibody | 1200 mg | — |
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Comparator | Doxorubicin | Other / unclassified | 40 mg/m2 | — |
| Comparator | Doxorubicin | Other / unclassified | 60 mg/m2 | — |
| Comparator | Paclitaxel | Small molecule | 125 mg/m2 | — |
| Comparator | Paclitaxel | Small molecule | 175 mg/m2 | — |